Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print          Annual reports

Friday 02 July, 2021

Alliance Pharma PLC

Block Listing Six Monthly Return

RNS Number : 0142E
Alliance Pharma PLC
02 July 2021
 

 

For immediate release

2 July 2021

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Block Listing Six Monthly Return

 

Name of applicant:

ALLIANCE PHARMA PLC

Names of schemes:

a)  The Alliance Pharma plc Approved Share Option Plan 2005

b)  The Alliance Pharma plc Share Option Plan 2006

c)  The Alliance Pharma plc Company Share Option Plan 2015

Period of return:

From:

28 December 2020

To:

28 June 2021

Number of securities originally admitted at date of admission:

25,000,000 ordinary shares of 1p each

28 June 2017

Balance of unallotted securities under schemes from previous return:

a)  293,372

b)  5,266,622

c)  13,265,746

Plus:   The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):

a)  Nil

b)  Nil

c)  Nil

Less:   Number of securities issued/allotted under schemes during period:

a)  258,052

b) 317,909

c)  1,816,189

 

Equals:   Balance under schemes not yet issued/allotted at end of period:

d)  35,320

e)  4,948,713

f)  11,449,557

 

Name of contact:

Chris Chrysanthou, Company Secretary

Telephone number of contact:

Tel. +44 (0)1249 705166

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer


Andrew Franklin, Chief Financial Officer


www.alliancepharma.co.uk


Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Oliver Steele


Corporate Broking: James Black


 

Investec Bank plc

+ 44 (0) 20 7597 5970

Corporate Finance: Daniel Adams


Corporate Broking: Patrick Robb


 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUUUKRABUBRRR

a d v e r t i s e m e n t